Print Leuprolide acetate (Lupron®)

Leuprolide acetate (Lupron®)

 

POLICY NUMBER

L.5.01.446

 

DESCRIPTION

Leuprolide acetate (Lupron®), a luteinizing hormone-releasing hormone agonist, is a synthetic analog of naturally occurring gonadotropin-releasing hormone (GnRH) possessing greater potency than the natural hormone. Initially, leuprolide acetate (Lupron®) increases circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in gonadal steroids (testosterone and dihydrotestosterone in males; estrone and estradiol in premenopausal females.) However, continuous daily administration results in decreased LH and FSH in all patients. In males, testosterone levels decrease to castrate levels, and in premenopausal females, estrogens are reduced to postmenopausal levels. These decreases occur within 2 to 4 weeks after initiation of therapy.

FDA approved indications are as follows:

  • Endometriosis
  • Precocious puberty
  • Prostate cancer, palliative treatment of advanced disease
  • Uterine leiomyomata

 

POLICY

Leuprolide (Lupron®) is considered medically necessary for the following disease states:

  • Endometriosis
  • Uterine leiomyomata
  • Precocious puberty
  • Prostate cancer
  • Breast cancer
  • Endometrial cancer

Leuprolide (Lupron®) is considered not medically necessary for ovarian stimulation.

 

POLICY EXCEPTIONS

None

 

POLICY GUIDELINES

The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.

Medically Necessary is defined as those services, treatments, procedures, equipment, drugs, devices, items or supplies furnished by a covered Provider that are required to identify or treat a Member's illness, injury or Nervous/Mental Conditions, and which Company determines are covered under this Benefit Plan based on the criteria as follows in A through D:

A.  consistent with the symptoms or diagnosis and treatment of the Member's condition, illness, or injury; and

B.  appropriate with regard to standards of good medical practice; and

C.  not solely for the convenience of the Member, his or her Provider; and

D.  the most appropriate supply or level of care which can safely be provided to Member. When applied to the care of an Inpatient, it further means that services for the Member's medical symptoms or conditions require that the services cannot be safely provided to the Member as an Outpatient.

For the definition of Medically Necessary, “standards of good medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. BCBSMS makes no payment for services, treatments, procedures, equipment, drugs, devices, items or supplies which are not documented to be Medically Necessary. The fact that a Physician or other Provider has prescribed, ordered, recommended, or approved a service or supply does not in itself, make it Medically Necessary.

Investigative is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized as a generally accepted standard of good medical practice for the treatment of the condition being treated and; therefore, is not considered medically necessary. For the definition of Investigative, “generally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting.

 

POLICY HISTORY

5/1999: Approval by Pharmacy & Therapeutics Committee (P & T)

11/1999: Revisions approved by P & T

1/17/2001: Added new HCPCS J9219 effective 1-01-2001

4/9/2001: Breast and Endometrial cancer added as covered indications, ICD-9 diagnosis code 174.0-174.9, 175.0-175.9, 182.0 added covered codes

1/30/2002: Prior authorization deleted

2/14/2002: Investigational definition added

5/1/2002: Type of Service and Place of Service deleted

11/13/2002: ICD-9 diagnosis codes moved to Code Reference section

9/10/2004: Code Reference section updated, ICD-9 diagnosis code range 174.0-174.9, 218.0-218.9, 617.0-617.9 listed separately, ICD-9 diagnosis code 173.5, 198.2, 198.81, 198.82, 232.5, 233.0, 233.2 added covered codes, ICD-9 diagnosis code 259.0 deleted covered codes, HCPCS S9560 added covered codes, non-covered codes table deleted, ICD-9 diagnosis code 256.4, 183.0, 198.6, 233.3 deleted non-covered codes, Catamenial pneumothorax, hypersexuality, ovarian stimulation deleted non-covered table

9/16/2005: Code Reference section updated, CPT code 90782 deleted, ICD-9 diagnosis code 233.4 added

10/29/2006: Dosing and off-label information removed

11/2/2006: Code Reference updated. ICD-9 diagnosis codes 173.5, 174-174.6, 174.8, 174.9, 175.0-175.9, 182.0, 198.2, 198.81, 232.5, 233.0 deleted from policy

7/12/2007: Code Reference updated. ICD-9 diagnosis codes 173.5, 174-174.6, 174.8, 174.9, 175.0-175.9, 182.0, 198.2, 198.81, 232.5, 233.0 added to policy. Breast and endometrial cancer added to policy statement as medically necessary. Ovarian stimulation (256.1) added to policy statement as not medically necessary.

8/25/2008: Added ICD-9 diagnosis code range 256.0 - 256.9 as not medically necessary for ovarian stimulation

04/01/2014: Policy title changed from "Leuprolide (Lupron®)" to "Leuprolide acetate (Lupron®)." Policy description updated to add "acetate" to Leuprolide (Lupron®). Policy statement intent unchanged.

09/01/2015: Code Reference section updated for ICD-10. Extended ICD-9 diagnosis code 173.5 to the fifth digit as 173.50, 173.51, 173.52, and 173.59.

05/27/2016: Policy number added. Policy Guidelines updated to add medically necessary and investigative definitions.

06/13/2016: Approved by Pharmacy & Therapeutics (P&T) Committee.

 

SOURCE(S)

American Hospital Formulary Services 1998

Fact and Comparisons October, 1999

Micromedex, 1998, 2006

Lupron® Prescribing Information

 

CODE REFERENCE

This may not be a comprehensive list of procedure codes applicable to this policy.

The code(s) listed below are ONLY medically necessary if the procedure is performed according to the "Policy" section of this document.

Covered Codes

Code Number

Description

CPT-4

  

HCPCS

J1950

Injection, leuprolide acetate (for depot suspension), per 3.75 mg.

J9217

Leuprolide acetate (for depot suspension), 7.5 mg.

J9218

Leuprolide acetate, per 1 mg.

J9219

Leuprolide acetate implant, 65 mg

S9560

Home injectable therapy; hormonal therapy (e.g.; leuprolide, goserelin), including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

ICD-9 Procedure

ICD-10 Procedure

  

 

 

ICD-9 Diagnosis

ICD-10 Diagnosis

173.50, 173.51, 173.52, 173.59

Other malignant neoplasm of skin of trunk, except scrotum

C44.501, C44.511, C44.521, C44.591

Other and unspecified malignant neoplasm of skin of breast

174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9

Malignant neoplasm of female breast

C50.011, C50.012, C50.019, C50.111, C50.112, C50.119, C50.211, C50.212, C50.219, C50.311, C50.312, C50.319, C50.411, C50.412, C50.419, C50.511, C50.512, C50.519, C50.611, C50.612, C50.619, C50.811, C50.812, C50.819, C50.911, C50.912, C50.919

Malignant neoplasm of breast, female

175.0, 175.9

Malignant neoplasm of male breast

C50.021, C50.022, C50.029, C50.121, C50.122, C50.129, C50.221, C50.222, C50.229, C50.321, C50.322, C50.329, C50.421, C50.422, C50.429, C50.521, C50.522, C50.529, C50.621, C50.622, C50.629, C50.821, C50.822, C50.829, C50.921, C50.922, C50.929

Malignant neoplasm of breast, male

182.0

Malignant neoplasm of corpus uteri, except isthmus (endometrial cancer)

C54.1 - C54.9

Malignant neoplasm of corpus uteri, except isthmus

185

Malignant neoplasm of prostate

C61

Malignant neoplasm of prostate

198.2

Secondary malignant neoplasm of skin

C79.2

Secondary malignant neoplasm of skin

198.81

Secondary malignant neoplasm of breast

C79.81

Secondary malignant neoplasm of breast

198.82

Secondary malignant neoplasm of genital organs

C79.82

Secondary malignant neoplasm of genital organs

218.0, 218.1, 218.2, 218.9

Uterine leiomyoma

D25.0, D25.1, D25.2, D25.9

Uterine leiomyoma

232.5

Carcinoma in situ of skin of trunk, except scrotum

D04.5

Carcinoma in situ of skin of trunk

233.0

Carcinoma in situ of breast

D05.00 - D05.92

Carcinoma in situ of breast

233.2

Carcinoma in situ of other and unspecified parts of uterus

D07.0

Carcinoma in situ of endometrium

233.4

Carcinoma in situ of prostate

D07.5

Carcinoma in situ of prostate

259.1

Precocious sexual development and puberty, not elsewhere classified

E30.1

Precocious puberty

617.0, 617.1, 617.2, 617.4, 617.5, 617.6, 617.8, 617.9

Endometriosis

N80.0, N80.1, N80.2,

N80.4, N80.5, N80.6, N80.8, N80.9

Endometriosis

Top